FDA Approved First Size-Adjustable Pediatric Heart Valve

The new valve expands with a balloon catheter to help children avoid repeat open-heart surgeries.

Updated on Oct. 1, 2026 in Heart Disease

Isometric editorial illustration of a synthetic heart valve device rendered in matte oxblood and slate blue against a cream background. — The FDA has approved the Autus Size-Adjustable Valve, the first pediatric heart valve capable of expanding to accommodate child growth. AI Illustration. Upload story photo >

Live Poll

Do you believe new medical technologies effectively improve long-term healthcare outcomes for children?

The FDA has granted approval for the Autus Size-Adjustable Valve, a new medical device designed for pediatric patients with congenital pulmonary valve disease. The valve uses innovative polymeric materials and can be widened via balloon catheter as a child grows.

Why it matters

This device aims to reduce the number of invasive open-heart surgeries pediatric patients must undergo throughout their childhood. By growing alongside the patient, it offers a durable alternative to traditional, static replacements.

The valve diameter expands from approximately 13 millimeters to 22 millimeters to accommodate growth. Clinical results from 62 pediatric patients showed acceptable hemodynamic performance at the six-month follow-up.

The players

FDA

The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical devices.

Edwards Lifesciences

This company is a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring.

Autus Valve Technologies Inc.

This medical technology firm focuses on developing advanced solutions for treating pediatric heart conditions.

The details

Developed by Autus Valve Technologies Inc. and approved for distribution by Edwards Lifesciences, this is the first U.S.-approved valve to utilize polymeric leaflets instead of animal-derived tissue. The material is specifically engineered to resist the hardening and degradation common in conventional prosthetic valves.

October 1, 2026: The FDA officially approved the Autus Size-Adjustable Valve.
6 months post-implantation: Patients in the study demonstrated successful hemodynamic performance.

Heart Disease
Sept. 30
FDA Approved Camzyos for Pediatric Heart Condition
Robotics
Sept. 28
FDA Authorized Johnson & Johnson Surgical Robot
Biotech
Sept. 23
Heidi Overton Will Address Senate on FDA Strategy

The Big Picture

This development represents a shift toward dynamic, growth-accommodating implants within the FDA premarket approval pathway. It highlights a departure from static prosthetic designs that previously necessitated repeated surgical interventions as children outgrew their devices.

Pediatric patients who require pulmonary valve intervention may face fewer repeat surgeries as they grow into adolescence. Families should consult with their pediatric cardiologists to determine if this new technology is an appropriate treatment option for their child.

The takeaway

This new technology demonstrates the potential for medical devices to evolve with a patient throughout their development. It represents a significant step forward in reducing the physical and psychological burden of repeat surgeries for children with congenital heart conditions.